SpringTide Ventures

SpringTide Ventures Research Investment Thesis SpringTide Ventures is a specialized health-tech venture capital firm founded in 2018 by repeat healthcare founders who have previously started, scaled, and exited healthcare companies. The firm is built on the conviction that the greatest health-tech innovations come from founders with deep healthcare experience and entrepreneurial track records. SpringTide leads early-stage financings for tomorrow's greatest healthcare companies, with an embedded Chief Medical Officer and clinical operators who provide hands-on support to founders tackling underserved patient populations and broken healthcare delivery models. The firm operates with a unique infrastructure: 22 venture partners providing direct access to policymakers and system leaders, alongside a 114-person investor network. This structure allows SpringTide to do more than provide capital—they offer operational expertise, regulatory guidance, and access to high-value relationships across healthcare delivery, payers, and policy. Stage Focus SpringTide Ventures invests primarily in Pre-Seed, Seed, and Series A stages: Pre-Seed: Early-stage validation with working prototypes Seed: Companies with initial traction and product-market fit signals Series A: Selected follow-ons for companies with strong momentum The firm is not a late-stage investor. Their sweet spot is identifying exceptional teams early and providing deep operational support through critical inflection points. Check Size Typical investment range: $500K - $5M Pre-Seed: $500K - $1.5M Seed: $1M - $3M Series A: $2M - $5M (selective) Based on their portfolio and fund size, SpringTide typically targets 10-15% ownership stakes in their investments, giving them board influence while leaving significant upside for founders and follow-on investors. Lead Tendency SpringTide leads the majority of their investments . This is reflected across their portfolio: Leads seed rounds with clean terms Co-leads larger rounds with experienced co-investors Occasionally participates in Series A follow-ons for exceptional companies Their track record shows strong conviction in the companies they back, with most investments seeing them in the lead or co-lead position. Recent Activity SpringTide Ventures Fund III closed in late 2025 at $150M ("raised much of our vintage 2025, $150M Fund III at this point" - Feb 2026). The firm is actively deploying capital with recent investments including: 2025-2026 Recent Investments: December 2025: WearLinq ($14M Series A, co-investor) - wireless cardiac monitoring wearables 2025: Pinch - clinical care delivery 2025: Dopl Technologies - telesurgery platform 2025: Janie - healthcare practice automation using AI/digital workers Fund II Performance: Fund II closed at $65M in April 2024 Total assets under management now exceed $150M (Fund III) High-quality portfolio demonstrating strong outcomes Portfolio Highlights Notable Active Companies: Paterna Biosciences - Revolutionary fertility tech creating functional sperm through in vitro spermatogenesis for male infertility treatment (pre-clinical, high impact) OpenLoop - Telehealth infrastructure powering 120+ clients across all 50 states, 250,000+ visits per month, AI-enabled workflows FlyteHealth - Obesity management platform combining GLP-1 medications with behavior coaching and personalized care Tenovi - Remote patient monitoring with low-tech accessibility (180,000+ devices deployed nationwide) Wellsheet - Clinical workflow automation recognized by Business Insider as a top healthcare startup 2025 Nest Health - In-home primary care for families, serving underinsured populations with whole-family health model Ellipsis Health - Mental health diagnostic using voice analysis and AI to identify depression and anxiety at scale Biotia - Next-generation sequencing and AI for precision infectious disease discovery Debut Biotech - AI-driven beauty biotech (TIME100 most innovative company 2025) Helm Health - Healthcare price transparency and shopping platform Inito - Advanced health tracking with focus on fertility monitoring (8x growth 2022, 4x projected 2023) IgniteData - EHR-to-EDC data transfer for clinical trials Leash Bio - ML-driven medicinal chemistry with purpose-built datasets Notable Exits: Pathology Watch (acquired by Sonic Healthcare for $150M, 2024) Multiple companies demonstrating strong exit potential Team & Leadership Austin Walters, Managing Partner Operational and strategic leadership Featured in Forbes discussing 2025 VC trends and AI investment landscape Strong voice on practical AI applications in healthcare Josh Cowdin, Chief Financial Officer Founding CEO of Belltower Fund Group (AngelList's fund administration spinoff) Former CFO and Managing Director of Investor Relations at Banner Capital 10+ years in leadership at Strata Fund Solutions and Alter Domus Deep expertise in fund operations and scaling service organizations Brad Otto, Partner - Healthcare expertise and deal leadership Claire Smith, Partner - Portfolio support and company operations Ryan Morley, Partner - Investment thesis and founder selection Team Structure: 41-person team including investment professionals, operational staff, and network partners 22 venture partners providing specialized expertise and deal access 114 investor network providing geographic coverage and deep relationships Embedded clinical operators and medical advisors Decision Process Structure: Partnership-based with collaborative investment committee SpringTide's decision process emphasizes team evaluation above all else. Partners note that they evaluate opportunities on three main factors: the team, the market, and the idea—with team being "by far the most important." Process characteristics: Founder-centric (built by repeat health-tech founders) Operational deep-dives before commitment Clinical validation integrated into diligence Board-level involvement post-investment Strong follow-on support and strategic guidance Founder Preferences SpringTide strongly favors: Repeat Healthcare Founders - Founders with prior healthcare company experience, exits, and operational scars Clinical Expertise - Founding teams including physicians, clinicians, or scientists who deeply understand the problems they're solving Problem Validation - Founders solving real, measurable healthcare delivery problems with direct stakeholder engagement Operational Sophistication - Teams that understand regulatory, reimbursement, and healthcare delivery complexity from day one Patient-Centric Focus - Founders obsessed with improving outcomes for underserved or overlooked patient populations Anti-thesis: Consumer apps without health outcomes, speculative biotech without experienced teams, and founders without healthcare domain expertise. Geographic Focus Primary regions: Boston Metro (Cambridge headquarters) - Deep healthcare ecosystem access San Francisco (secondary office) - Tech talent and AI/ML infrastructure expertise Salt Lake City (secondary office) - Emerging health-tech hub with strong founders US-focused with selective international interest in health-tech innovation The firm has expanded to three major locations to be close to both healthcare innovation hubs and tech talent centers. Fund Structure & Deployment Fund III: $150M (2025 vintage, actively deploying) Fund II: $65M (2024, completed deployment) Total AUM: Approximately $150M-$200M across active funds The firm is selective about fund size, keeping funds at $65-150M to maintain founder-focused attention and operational support quality. Notable Program: Wave Summit & Wave Labs SpringTide operates Wave (wave.springtide.com), a proprietary platform bringing together healthcare innovators, entrepreneurs, policymakers, and system leaders. Wave Summit is an annual gathering of 400+ health-tech founders and leaders; Wave Labs provides content platform and collaborative infrastructure. This is a significant value-add: networking, insights, and policy/payer relationship building for portfolio companies. Investment Philosophy SpringTide's philosophy centers on: Founders First - Built by and for repeat healthcare founders who understand the journey Real Problem Solving - Solving concrete healthcare delivery problems with measurable health outcomes Team > Idea - Operational excellence and healthcare domain expertise matter more than any single idea Systemic Thinking - Understanding how healthcare providers, payers, patients, and policy interconnect Long-Term Partnership - Active board participation, operational support, and network leverage throughout company lifecycle Underserved Populations - Special focus on companies improving health for underinsured and underserved populations Market Insight From Austin Walters' recent Forbes article, SpringTide is focused on: AI's practical impact on healthcare workflows (not hype) Value flowing to founders solving real operational problems Intersection of AI and physical healthcare systems Avoiding commoditized software in favor of differentiated applications Recent Fund Announcements Fund III close: Late 2025, $150M raised Managing Partner commentary: "We've raised much of our vintage 2025, $150M Fund III. One LP asked why not raise more?" (Feb 3, 2026) - indicating strong demand and intentional sizing Team expansion: Recent hire of Chief Financial Officer (Josh Cowdin) signals operational scaling Why Founders Choose SpringTide Founder-Led Firm - No finance guys, operating partners with healthcare track records Fast Decision-Making - Partnership structure enables quick yes/no decisions Operational Support - 22 VPs and 114 investor network provides unmatched go-to-market support Healthcare Credibility - Direct relationships to payers, providers, and policymakers Warm Intro Culture - Wave Summit and investor network make warm intros valuable currency Patient Impact Focus - Shared obsession with improving health outcomes, not just exits Sector Focus Summary While officially focused on healthcare_digital broadly, SpringTide's real investment pattern shows concentration in: Digital health and telehealth (OpenLoop, Ellipsis, Tenovi, Nest Health) Reproductive health and fertility (Paterna Biosciences, Inito) Chronic disease management (FlyteHealth, Tenovi) Clinical operations and workflow (Janie, Wellsheet) Biotech and precision medicine (Biotia, Leash Bio, Paterna) Healthcare infrastructure (data, operations, compliance) Notable: NOT focused on pure medical devices, hardware (except in data collection), or capital equipment. Investment Momentum The firm is in excellent shape: Fund III deployed multiple investments already by late 2025 Strong portfolio company momentum (multiple in Business Insider "Most Promising" lists) Exceptional exit potential (Pathology Watch $150M exit validates thesis) Expanding team (adding CFO, investor intern roles open) signals growth Wave platform gaining traction as strategic asset